Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 4966 to 4980 of 7688 results

  1. NICE encourages further research into optical coherence tomography (OCT) to guide PCI compared against percutaneous coronary intervention (PCI) with no intravascular imaging or PCI with intravascular ultrasound. Research outcomes should include data on medium- and long-term clinical outcomes, including the need for revascularisation.

    Recommendation ID IPG481/1 Question NICE encourages further research into optical coherence tomography (OCT) to guide PCI compared against

    Research recommendation
    Published
    9 June 2015

  2. NICE encourages further research into percutaneous electrical nerve stimulation (PENS) for refractory neuropathic pain, particularly to provide more information about selection criteria and long-term outcomes, with clear documentation of the indications for treatment.

    Recommendation ID IPG450/1 Question NICE encourages further research into percutaneous electrical nerve stimulation (PENS) for refractory

    Research recommendation
    Published
    9 June 2015

  3. Neuropathic pain relief:- Does early treatment with a centrally acting analgesic (for example pregabalin) reduce the frequency or severity of neuropathic pain in people with spinal cord injury?

    Recommendation ID NG41/1 Question Neuropathic pain relief:- Does early treatment with a centrally acting analgesic (for example pregabalin)

    Research recommendation
    Published
    4 April 2016

  4. NICE encourages further research comparing ultrasound-enhanced, catheter-directed thrombolysis for deep vein thrombosis against catheter-directed thrombolysis alone. Patient selection should be documented, including the duration and extent of thrombosis. The dose of thrombolytic agent used and the duration of thrombolysis should be reported, together with all complications. Outcome measures should include the success of thrombolysis (complete, partial or failed) and long-term sequelae. NICE may update the guidance on publication of further evidence.

    Recommendation ID IPG523/1 Question NICE encourages further research comparing ultrasound-enhanced, catheter-directed thrombolysis for

    Research recommendation
    Published
    5 October 2015

  5. NICE encourages further research into percutaneous electrothermal treatment of the intervertebral disc  annulus. Further research should document details of patient selection, including the duration of their symptoms. It should report precise details of the technique used for treatment. Outcome measures should include pain relief and quality of life. Long-term follow-up data should include details of any subsequent procedures.

    Recommendation ID IPG544/1 Question NICE encourages further research into percutaneous electrothermal treatment of the intervertebral disc

    Research recommendation
    Published
    15 March 2016

  6. NICE encourages further research into arthroscopic trochleoplasty for patellar instability, including publication of consecutive patient series. Patient selection should be described in detail. Reported outcomes should include functional and quality‑of‑life measures, as well as reoperation rates.

    Recommendation ID IPG474/1 Question NICE encourages further research into arthroscopic trochleoplasty for patellar instability, including

    Research recommendation
    Published
    9 June 2015

  7. NICE encourages further research into transcranial direct current stimulation (tDCS) for depression, which should document how patients were selected and any other treatments they were having. It should describe the precise method and regime used for administering tDCS. Outcome measures should include the duration of effect. NICE may update the guidance on publication of further evidence.

    Recommendation ID IPG530/1 Question NICE encourages further research into transcranial direct current stimulation (tDCS) for depression

    Research recommendation
    Published
    12 October 2015

  8. NICE encourages further research into percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back pain. Further research should include details of patient selection, the duration of patients' symptoms, and a precise account of the technique used for treatment. Outcome measures should include pain relief and quality of life. Long-term follow-up data shouldinclude details of any subsequent procedures.

    Recommendation ID IPG545/1 Question NICE encourages further research into percutaneous intradiscal radiofrequency treatment of the intervertebral

    Research recommendation
    Published
    15 March 2016

  9. NICE encourages further research into balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Details of patient selection, all complications, and subsequent treatments and interventions for pulmonary hypertension should be collected. Reports should include quality-of-life outcomes, long-term efficacy outcomes and survival. NICE may update the guidance on publication of further evidence.

    Recommendation ID IPG554/1 Question NICE encourages further research into balloon pulmonary angioplasty for chronic thromboembolic pulmonary

    Research recommendation
    Published
    4 May 2016

  10. NICE encourages further research into preoperative high dose rate brachytherapy for rectal cancer. Trials should be designed to provide clear data on the efficacy of this procedure, whether or not other adjunctive treatments are used. Research should document adjunctive treatments and details of patient selection. Outcomes should include local recurrence, survival, disease-free survival and quality of life. NICE may update the guidance on publication of further evidence.

    Recommendation ID IPG531/1 Question NICE encourages further research into preoperative high dose rate brachytherapy for rectal cancer.

    Research recommendation
    Published
    12 October 2015

  11. Newly diagnosed seizures (focal and generalised) – monotherapy: How do the newer AEDs compare in efficacy to the standard AEDs in the treatment of newly diagnosed epilepsy? Focal seizures: carbamazepine, eslicarbazepine acetate, lacosamide, lamotrigine, levetiracetam, pregabalin  and zonisamide. Generalised seizures: lamotrigine, levetiracetam, sodium valproate and zonisamide.

    Recommendation ID CG137/1 Question Newly diagnosed seizures (focal and generalised) – monotherapy: How do the newer AEDs compare in efficacy

    Research recommendation
    Published
    13 August 2021

  12. NICE encourages further research into ultrasound-enhanced, catheter-directedthrombolysis for pulmonary embolism. Ideally this should include comparative studies against catheter-directed thrombolysis alone. Patient selection should be  documented. The dose of thrombolytic agent used and the duration of thrombolysis should be reported, together with all complications. Outcome measures should include the success of thrombolysis (complete, partial or failed) and long-term sequelae. NICE may update the guidance on publication of further evidence.

    Recommendation ID IPG524/1 Question NICE encourages further research into ultrasound-enhanced, catheter-directedthrombolysis for pulmonary

    Research recommendation
    Published
    6 October 2015

  13. NICE encourages further research into radiofrequency ablation for gastric antral vascular ectasia and collaborative publication of data from local audit. Patient selection should be clearly documented, including details of prior treatments. Outcomes should include success and duration of effect in controlling bleeding and the effect of this on the need for blood transfusion. All complications should be reported. NICE may update the guidance on publication of further evidence.

    Recommendation ID IPG520/1 Question NICE encourages further research into radiofrequency ablation for gastric antral vascular ectasia and

    Research recommendation
    Published
    6 October 2015

  14. NICE encourages further research into CXL using riboflavin and UVA for keratoconus and keratectasia, especially epithelium-on (transepithelial) CXL and the combination (CXL-plus) procedures. Details of the techniques used should be clearly described. Reported outcomes should include visual acuity, corneal topography and quality of life. Data on long-term outcomes for all types of CXL using riboflavin and UVA for keratoconus and keratectasia would be useful – specifically data about prevention of progression to corneal transplantation and about repeat procedures and their efficacy.

    Recommendation ID IPG466/1 Question NICE encourages further research into CXL using riboflavin and UVA for keratoconus and keratectasia

    Research recommendation
    Published
    9 June 2015

  15. NICE agreed that further research was needed because there is currently no clinical- or cost-effectiveness evidence evaluating the use of Holoclar in both eyes in bilateral patients. The committee was aware of the ongoing HOLOCORE trial which is recruiting both unilateral and bilateral patients, but only evaluates the success of a second transplant in 1 eye rather than transplant success in both eyes.

    Recommendation ID TA467/1 Question NICE agreed that further research was needed because there is currently no clinical- or cost-effectiveness

    Research recommendation
    Published
    15 October 2018